Abstract
Objective: ONC201 (Oncoceutics), a dopamine receptor D2 (DRD2) antagonist, is actively being explored in clinical trials for endometrial cancer (EC). DRD2 is a G protein-coupled receptor that activates the trimeric G-protein complex Ras, modulating downstream metabolic pathways such as Ras- and Akt-signaling, which are highly dysegulated in obesity-driven EC. Thus, we sought to investigate the antitumorigenic potential of ONC201 in a genetically engineered mouse model of endometrioid EC (LKB1fl/flp53fl/fl).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
